Digital polymerase chain reaction (d-PCR) is considered a next-generation PCR technology offering rapid, sensitive quantification of nucleic acid when compared to the conventional PCR technology. Digital PCR is highly precise, where each sample partitioned into a number of individualized reactions or as droplets in a droplet-based digital PCR. These partitioned droplets are analyzed after a separate PCR reaction takes place per single sample, and the absolute number of molecules present in the sample is calculated.
BIS Research healthcare experts have found digital PCR (d-PCR) market to be one of the most rapidly evolving markets and the global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025. The market is driven by certain factors, which include the rising incidence of infectious disease, such as recent pandemic COVID-19, inciting the development of high-throughput diagnostics, increasing adoption of personalized medicine for the screening and diagnostics of genetic disorders, and significant external funding for executing R&D exercises.
The market is favored by the development of digital PCR-based solutions for early diagnosis and rare mutation detection with absolute quantification of target sample. The gradual increase in the prevalence of infectious disease due to pandemic COVID-19 globally has furthered the digital PCR (d-PCR) market.
Furthermore, several diagnostic companies are focusing on the development of digital PCR diagnostics with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes.
Market Segmentation
• Product Type – Assays and Reagents, Platforms, Accessories, and Instruments
• Application- Clinical, Environmental Monitoring, Food and Agriculture and Others
• End User – Hospital and Clinics, Academic and Research Institutions, Diagnostic Centers, and Other End Users
Regional Segmentation
• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World
Growth Drivers
• Rising Incidence of Infectious Disease, such as recent pandemic COVID-19, Inciting the Development of High-throughput Diagnostics
• Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders
• Significant External Funding for Executive R&D Exercises
Market Challenges
• Shortage of Skilled Professionals and Trained Lab-Technicians
• High Cost of Platforms Associated with Digital-PCR
Market Opportunities
• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
• Technological Advancements in the development of Digital PCR-based Solutions
• Increased Use of Digital PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
Key Companies Profiled
Thermo Fisher Scientific, Bio-Rad Laboratories, Inc.., Optolane Technologies, Inc., Qiagen NV, Sysmex Corporation, SAGA Diagnostics AB, Stem Genomics, Fluidigm Corporation, Combinati, Merck KGaA, JN Medsys, Stilla Technologies, Dropworks, Inc. Naveris, Inc. Genetron Holdings Limited.
Request a Sample - https://bisresearch.com/requestsample?id=958&type=download
Comments
Post a Comment